# RGS13

## Overview
RGS13 is a gene that encodes the protein regulator of G protein signaling 13, a member of the RGS protein family. This family is characterized by its role in modulating G protein-coupled receptor (GPCR) signaling pathways through its function as a GTPase-activating protein (GAP). The RGS13 protein is part of the B/R4 subfamily, which includes proteins with short amino- and carboxy-terminal domains flanking the conserved RGS domain. This domain is essential for binding to Gα subunits and accelerating GTP hydrolysis, thereby influencing signal transduction processes. RGS13 is predominantly expressed in germinal center B lymphocytes and mast cells, where it plays a significant role in regulating immune responses by interacting with chemokine receptors and other signaling molecules. The protein's activity and stability are modulated by post-translational modifications, such as phosphorylation, which can enhance its function and prevent degradation. RGS13 has been implicated in various diseases, including cancer, where its expression levels and interactions with key signaling pathways may contribute to disease progression (Li2023RGS; Shi2002RGS13; Ross2000GTPaseActivating).

## Structure
RGS13 is a member of the RGS protein family, characterized by a conserved RGS domain approximately 120-130 amino acids in length, which is crucial for its function as a GTPase-activating protein (GAP) (Li2023RGS; Ross2000GTPaseActivating). This domain is composed of nine α-helices that form a globular, mostly helical structure based on a four-helix bundle, with additional N- and C-terminal helices (Li2023RGS; Ross2000GTPaseActivating). The RGS domain facilitates binding to Gα subunits, accelerating GTP hydrolysis, and modulating G protein signaling (Ross2000GTPaseActivating).

RGS13 is part of the B/R4 subfamily, which includes proteins with short amino- and carboxy-terminal domains flanking the RGS domain (Chidiac2003Activity). These proteins are generally smaller and may contain additional domains that facilitate membrane association (Chidiac2003Activity). RGS13 is noted for its preference for Gα_q over Gα_i/o subunits, indicating specific interactions within its tertiary structure that influence its selectivity (Masuho2020A).

Post-translational modifications, such as phosphorylation, can enhance RGS13 activity and block its degradation, affecting its stability and function (Li2023RGS). However, specific details about splice variant isoforms of RGS13 are not provided in the available context.

## Function
RGS13 is a member of the RGS protein family, which modulates G protein-coupled receptor (GPCR) signaling pathways by acting as a GTPase-activating protein (GAP) for Gα subunits, thereby accelerating the termination of GPCR signaling. In healthy human cells, RGS13 is primarily expressed in germinal center B lymphocytes and mast cells, where it plays a crucial role in regulating immune responses (Kehrl2016The; Shi2002RGS13).

RGS13 inhibits signaling pathways mediated by chemokine receptors CXCR4 and CXCR5, which are important for the migration and positioning of B cells within lymphoid tissues. This inhibition affects the phosphorylation of p42 MAPK, a key signaling molecule, following stimulation with chemokines CXCL12 and CXCL13 (Shi2002RGS13). RGS13 also interacts with and inhibits the activity of phosphatidylinositol-3-kinase (PI3K) in mast cells and phosphorylated cyclic AMP response element binding protein (pCREB) in B cells, influencing transcriptional activity (Kehrl2016The).

In terms of cellular localization, RGS13 is primarily found in the cytoplasm of B lymphocytes, with some membrane localization in germinal center B cells (Shi2002RGS13). Its expression and function are modulated by various stimuli, such as CD40 signaling, which can enhance its expression in B cells (Shi2002RGS13).

## Clinical Significance
RGS13 has been implicated in various diseases, particularly in the context of cancer. In ovarian cancer, RGS13 is part of a five-gene signature that is highly expressed in cancerous tissues compared to normal ovarian tissues. This signature is associated with poor prognosis, including high mortality and advanced-stage disease, suggesting that alterations in RGS13 expression may contribute to ovarian cancer progression (Hu2021Identification). The gene's involvement in key signaling pathways, such as ECM-receptor interaction and TGF-beta, further supports its role in cancer cell proliferation and invasion (Hu2021Identification).

RGS13's stability and function are also influenced by phosphorylation, which can affect its degradation and activity. Protein kinase A (PKA) enhances RGS13 activity by promoting its nuclear localization and preventing proteasome degradation, indicating that changes in its phosphorylation status could have implications for cancer and other diseases (Li2023RGS). While specific diseases directly resulting from RGS13 mutations are not detailed, its dysregulation in signaling pathways suggests a potential role in various pathologies, including immune-related conditions like allergies and asthma (Li2023RGS).

## Interactions
RGS13 interacts with various proteins and plays a role in modulating G protein-coupled receptor (GPCR) signaling pathways. It has a preference for interacting with Gα_q subunits over Gα_i/o subunits, highlighting its selectivity in G protein interactions (Masuho2020A). RGS13 also interacts with phosphatidylinositol-3-kinase (PI3K) in mast cells, inhibiting its activity, and with phosphorylated cyclic AMP response element binding protein (pCREB) in B cells, where it inhibits pCREB-mediated transcription (Kehrl2016The). 

In the context of immune signaling, RGS13 is part of the R4 family of RGS proteins, which are known to act as GTPase-activating proteins (GAPs) for Gα_i proteins, thus influencing chemokine receptor signaling (Kehrl2016The). The protein kinase A (PKA) enhances RGS13 activity by facilitating its nuclear localization and blocking its proteasome degradation through phosphorylation at Thr 41, indicating a regulatory mechanism that affects its stability and localization (Li2023RGS). These interactions and modifications underscore the role of RGS13 in cellular signaling and its potential impact on immune cell function.


## References


[1. (Kehrl2016The) John H. Kehrl. The impact of rgs and other g-protein regulatory proteins on gαi-mediated signaling in immunity. Biochemical Pharmacology, 114:40–52, August 2016. URL: http://dx.doi.org/10.1016/j.bcp.2016.04.005, doi:10.1016/j.bcp.2016.04.005. This article has 40 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.bcp.2016.04.005)

[2. (Li2023RGS) Lin Li, Qiang Xu, and Chao Tang. Rgs proteins and their roles in cancer: friend or foe? Cancer Cell International, April 2023. URL: http://dx.doi.org/10.1186/s12935-023-02932-8, doi:10.1186/s12935-023-02932-8. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12935-023-02932-8)

[3. (Hu2021Identification) Yuexin Hu, Mingjun Zheng, Shuang Wang, Lingling Gao, Rui Gou, Ouxuan Liu, Hui Dong, Xiao Li, and Bei Lin. Identification of a five-gene signature of the rgs gene family with prognostic value in ovarian cancer. Genomics, 113(4):2134–2144, July 2021. URL: http://dx.doi.org/10.1016/j.ygeno.2021.04.012, doi:10.1016/j.ygeno.2021.04.012. This article has 43 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ygeno.2021.04.012)

[4. (Ross2000GTPaseActivating) Elliott M. Ross and Thomas M. Wilkie. Gtpase-activating proteins for heterotrimeric g proteins: regulators of g protein signaling (rgs) and rgs-like proteins. Annual Review of Biochemistry, 69(1):795–827, June 2000. URL: http://dx.doi.org/10.1146/annurev.biochem.69.1.795, doi:10.1146/annurev.biochem.69.1.795. This article has 940 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1146/annurev.biochem.69.1.795)

[5. (Masuho2020A) Ikuo Masuho, Santhanam Balaji, Brian S. Muntean, Nickolas K. Skamangas, Sreenivas Chavali, John J.G. Tesmer, M. Madan Babu, and Kirill A. Martemyanov. A global map of g protein signaling regulation by rgs proteins. Cell, 183(2):503-521.e19, October 2020. URL: http://dx.doi.org/10.1016/j.cell.2020.08.052, doi:10.1016/j.cell.2020.08.052. This article has 85 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.cell.2020.08.052)

[6. (Chidiac2003Activity) Peter Chidiac and Anju A. Roy. Activity, regulation, and intracellular localization of rgs proteins. Receptors and Channels, 9(3):135–147, January 2003. URL: http://dx.doi.org/10.3109/10606820308244, doi:10.3109/10606820308244. This article has 34 citations.](https://doi.org/10.3109/10606820308244)

[7. (Shi2002RGS13) Geng-Xian Shi, Kathleen Harrison, Gaye Lynn Wilson, Chantal Moratz, and John H. Kehrl. Rgs13 regulates germinal center b lymphocytes responsiveness to cxc chemokine ligand (cxcl)12 and cxcl13. The Journal of Immunology, 169(5):2507–2515, September 2002. URL: http://dx.doi.org/10.4049/jimmunol.169.5.2507, doi:10.4049/jimmunol.169.5.2507. This article has 103 citations.](https://doi.org/10.4049/jimmunol.169.5.2507)